ArticleACS infectious diseases2020
A Semisynthetic Kanglemycin Shows In Vivo Efficacy against High-Burden Rifampicin Resistant Pathogens.
James Peek et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
9 papers cite it
this papercites it